Bauckneht M, Bertagna F, Donegani MI, et al. - This study sought to evaluate if the prognostic value of ¹⁸ F‐Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) in metastatic castration-resistant prostate cancer (mCRPC) extends to the estimation of systemic treatment response duration. Between 2005 and 2020, researchers retrospectively included mCRPC patients submitted to FDG-PET/CT in four Italian centers. They included 114 mCRPC patients followed up for a median interval lasting 15 months. This study’s findings demonstrate that FDG-PET/CT’s prognostic value extends to predicting treatment response duration in mCRPC, therefore potentially guiding the systemic treatment selection.